Associations - Augtyro (repotrectinib)

NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK1 fusion	Non Small Cell Lung Cancer	NTRK1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK3 fusion	Non Small Cell Lung Cancer	NTRK3 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
NTRK2 fusion	Non Small Cell Lung Cancer	NTRK2 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
ALK positive	Solid Tumor	ALK positive	Solid Tumor	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma	LMNA-NTRK1 fusion + NTRK1 G595R	Cholangiocarcinoma	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
ROS1 fusion + ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 fusion + ROS1 G2032R	Non Small Cell Lung Cancer	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3	repotrectinib Sensitive: C3 – Early Trials repotrectinib Sensitive : C3
CD74-ROS1 fusion	Non Small Cell Lung Cancer	CD74-ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Resistant: C4 – Case Studies repotrectinib Resistant : C4	repotrectinib Resistant: C4 – Case Studies repotrectinib Resistant : C4
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + repotrectinib Sensitive: D – Preclinical sotorasib + repotrectinib Sensitive : D	sotorasib + repotrectinib Sensitive: D – Preclinical sotorasib + repotrectinib Sensitive : D
ETV6-NTRK3 fusion	Neuroblastoma	ETV6-NTRK3 fusion	Neuroblastoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D
EGFR mutation + YAP1 overexpression	Lung Adenocarcinoma	EGFR mutation + YAP1 overexpression	Lung Adenocarcinoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
EGFR mutation + YES1 overexpression	Lung Adenocarcinoma	EGFR mutation + YES1 overexpression	Lung Adenocarcinoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
ALK positive + YES1 overexpression	Lung Adenocarcinoma	ALK positive + YES1 overexpression	Lung Adenocarcinoma	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
ROS1 D2033N	Non Small Cell Lung Cancer	ROS1 D2033N	Non Small Cell Lung Cancer	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
ROS1 mutation	Non Small Cell Lung Cancer	ROS1 mutation	Non Small Cell Lung Cancer	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D	repotrectinib Sensitive: D – Preclinical repotrectinib Sensitive : D
KRAS G12D + KRAS G12V	Pancreatic Cancer	KRAS G12D + KRAS G12V	Pancreatic Cancer	repotrectinib + VS-6766 Sensitive: D – Preclinical repotrectinib + VS-6766 Sensitive : D	repotrectinib + VS-6766 Sensitive: D – Preclinical repotrectinib + VS-6766 Sensitive : D
KRAS G12D + KRAS G12V	Non Small Cell Lung Cancer	KRAS G12D + KRAS G12V	Non Small Cell Lung Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D	trametinib + repotrectinib Sensitive: D – Preclinical trametinib + repotrectinib Sensitive : D

Augtyro (repotrectinib)

Associations
(27)

Associations
(27)

Augtyro (repotrectinib)

Associations(27)

Associations(27)

Associations
(27)

Associations
(27)